Design, Synthesis, and Biological Evaluation of Thienopyrimidine Derivatives as Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: WANG, Jiang (Shanghai Institute of Materia Medica, shanghai, China)
- Co-author(s): Jiang Wang: Shanghai Institute of Materia Medica, shanghai, China
Hong liu: Shanghai Institute of Materia Medica, shanghai, China
Type 2 diabetes mellitus (T2DM) is the most common form of the diabetes disease, accounting for about 90-95% of all diagnosed North American cases of diabetes. DPP-4 inhibitors have emerged as a new therapeutic option to treat type 2 diabetes.
AimsTo discovery and development of novel DPP-4 inhibitors as a new therapeutic metord for the .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.